LARIMAR THERAPEUTICS

Larimar Therapeutics Reports First Quarter 2025 Financial Results

30 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

24 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

03 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

23 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

16 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

18 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

30 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

19 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in Upcoming Investor Conferences

27 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

30 May 2024 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

20 May 2024 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

14 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

11 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

06 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

16 Feb 2024 16:20:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

14 Feb 2024 06:15:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Proposed Underwritten Public Offering

13 Feb 2024 16:18:34 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

12 Feb 2024 07:00:00 By Nasdaq GlobeNewswire